Zimmer Biomet Holdings, Inc. $ZBH Shares Bought by Farther Finance Advisors LLC

Farther Finance Advisors LLC grew its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 25.3% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 9,145 shares of the medical equipment provider’s stock after purchasing an additional 1,845 shares during the quarter. Farther Finance Advisors LLC’s holdings in Zimmer Biomet were worth $834,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Ameriprise Financial Inc. increased its holdings in shares of Zimmer Biomet by 236.0% in the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock valued at $517,039,000 after acquiring an additional 3,208,596 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Zimmer Biomet by 251.3% during the first quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock worth $235,571,000 after purchasing an additional 1,488,918 shares during the period. Nuveen LLC acquired a new position in shares of Zimmer Biomet in the 1st quarter valued at about $155,891,000. Alyeska Investment Group L.P. bought a new stake in shares of Zimmer Biomet during the 1st quarter valued at about $101,294,000. Finally, Boston Trust Walden Corp acquired a new stake in Zimmer Biomet during the first quarter worth about $54,108,000. 88.89% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the transaction, the senior vice president owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.39% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on ZBH shares. Redburn Partners set a $130.00 target price on Zimmer Biomet in a report on Thursday, September 18th. Evercore ISI lowered their price objective on Zimmer Biomet from $102.00 to $96.00 and set an “in-line” rating for the company in a research note on Tuesday, July 8th. Rothschild Redb upgraded Zimmer Biomet to a “strong-buy” rating in a research note on Thursday, September 18th. Rothschild & Co Redburn initiated coverage on shares of Zimmer Biomet in a report on Thursday, September 18th. They set a “buy” rating and a $130.00 price target for the company. Finally, Raymond James Financial lifted their price objective on shares of Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Zimmer Biomet has a consensus rating of “Moderate Buy” and an average price target of $113.16.

Zimmer Biomet Trading Down 2.1%

NYSE:ZBH opened at $96.94 on Friday. The stock’s 50-day moving average is $100.48 and its two-hundred day moving average is $99.23. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The stock has a market cap of $19.20 billion, a PE ratio of 23.59, a price-to-earnings-growth ratio of 2.28 and a beta of 0.68. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $89.22 and a fifty-two week high of $114.72.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.98 by $0.09. The business had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. Zimmer Biomet’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the prior year, the business posted $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. Zimmer Biomet’s payout ratio is presently 23.36%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.